Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon

Cancer

Volumn 115, Issue 9, 2009, Pages 1859-1866

  Plimack, Elizabeth R ^b   Tannir, Nizar ^a   Lin, E ^a   Bekele, B Nebiyou ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Bevacizumab; Erlotinib; Immunotherapy; Interferon; Metastases; Renal cell carcinoma; Response criteria; Sorafenib; Survival

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; SORAFENIB; VASCULAR TARGETING AGENT;

ADULT; ANATOMY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PANCREAS METASTASIS; PERFORMANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN METASTASIS; VISCERAL METASTASIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65649108112     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24211     Document Type: Article

References (17)

1. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators, Lancet. 1999;353:14-17.
2. McDermott D. F. Regan M. M. Clark J. I. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141. (Pubitemid 41702632)
3. Yang J. C. Haworth L. Sherry R. M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. (Pubitemid 36910021)
4. Escudier B. Eisen T. Stadler W. M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
5. Motzer R. J. Hutson T. E. Tomczah P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
6. Ljungberg B. Alamdari F. I. Rasmuson T. Roos G. Followup guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405-411. (Pubitemid 29419406)
7. Therasse P. Arbuck S. G. Eisenhauer E. A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
8. Sivaramakrishna B. Gupta N. P. Wadhwa P. et al. Pattern of metastases in renal cell carcinoma; a single institution study. Indian J Cancer. 2005;42:173-177.
9. Lee D. S. White D. E. Hurst R. Rosenberg S. A. Yang JC. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 -based immunotherapy. Cancer J Sci Am. 1998;4:86-93. (Pubitemid 29090712)
10. Haas N. B. Uzzo RG. Tyrosine kinase inhibitors and antiangiogenic therapies in kidney cancer. Curr Treat Options Oncol. 2007;8:211-226. (Pubitemid 47362764)
11. Hahn O. Stadler W. Sorafenib. Curr Opin Oncol 2006;18:615-621.
12. Jacobsohn K. M. Wood CG. Adjuvant therapy for renal cell carcinoma. Sernin Oncol 2006;33:576-582. (Pubitemid 44511976)
13. Shuch B. Riggs S. B. Larochelle J. C. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and Implications for a new treatment paradigm. BJU Int. 2008;102:692-696.
14. Benjamin R. S. Choi H. Macaplnlac H. A. et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764. (Pubitemid 46797958)
15. Gollob J. A. Bonomi P. Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006;20:10-18.
16. Tuma RS. Sometimes size doesn't matter; reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst. 2006;98:1272-1274.
17. Choi H. Charnsangavej C. Faria S. C. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759. (Pubitemid 46797957)